Welcome to our dedicated page for Aspira Women`s Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women`s Health stock.
Aspira Women’s Health Inc. (formerly trading on Nasdaq under AWH) generates frequent news as a bio-analytical based women’s health company focused on noninvasive, AI-powered diagnostic tests for gynecologic diseases. Its updates often center on the commercial performance of OvaSuiteSM, which includes the OvaWatch® and Ova1Plus® blood tests for assessing ovarian cancer risk in women with adnexal masses.
News coverage commonly includes quarterly and annual financial results, where Aspira reports product revenue, OvaSuite test volumes, gross profit, operating expenses, and net loss. These releases may also describe changes in sales productivity, cost controls, and balance sheet items such as cash, liabilities, and stockholders’ deficit.
Another key category of Aspira news involves its research and development pipeline, particularly the ENDOinform™ program. The company has issued multiple announcements about its milestone-based award from the ARPA-H Sprint for Women’s Health initiative, detailing milestone achievements, associated cash payments, and progress toward a non-invasive, AI-enabled blood test for endometriosis using protein and microRNA biomarkers plus patient data.
Corporate governance and capital markets developments are also frequent topics. Aspira has reported Board and executive appointments, equity and convertible note financings, and changes in its listing status, including a delisting notification from Nasdaq and subsequent trading on OTC markets under related symbols. Together, these news items provide investors and observers with insight into Aspira’s diagnostic portfolio, pipeline evolution, financial condition, and corporate actions.
For anyone tracking AWH-related news, this page aggregates press releases and other coverage related to ovarian cancer risk assessment tests, endometriosis diagnostics development, ARPA-H milestones, financial updates, and boardroom or listing changes.
Aspira Women’s Health, Inc. (Nasdaq: AWH) announced its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29, 2021, at 4:40 PM ET. The event will include virtual 1x1 meetings with management, and interested parties can request meetings via email. Aspira focuses on innovative testing options for women’s health, particularly in ovarian cancer risk assessment and pelvic diseases. The company is developing next-generation products such as OVAWatch and EndoCheck. For more details, visit www.aspirawh.com.
Aspira Women’s Health (Nasdaq: AWH) is marking Ovarian Cancer Awareness Month by ringing the closing bell at NASDAQ on September 9, 2021, to promote awareness and access to risk assessment for ovarian cancer. Despite being a leading cause of cancer deaths in women, awareness remains low. Aspira aims to enhance knowledge on ovarian cancer through participation in various events, including keynote speeches and congressional briefings. The company is focused on developing innovative testing solutions to improve women’s healthcare and reduce disparities in risk assessment.
Aspira Women’s Health reported a strong second quarter for 2021, with total revenue increasing by 141% to $1.8 million compared to $743,000 in Q2 2020. The volume of OVA1 tests grew by 85% to 4,553 accessions. A recent publication supports OVA1's superiority over standard care for early-stage ovarian cancer detection. However, expenses surged, with research and development costs rising 287% and sales and marketing up by 132%. The company ended the quarter with $53 million in cash but reported a $6.5 million operational cash burn.
Aspira Women’s Health (AWH) will release its second quarter financial results for the period ending June 30, 2021, on August 12, 2021, after market close. An investor conference call will follow at 4:30 p.m. ET, where important updates and performance metrics will be discussed. Aspira is focused on women’s health, particularly in ovarian cancer risk assessment, offering FDA-cleared products like OVA1® and OVERA®. The company aims to develop innovative bio-analytical solutions to improve gynecologic health outcomes.
Aspira Women’s Health Inc. (Nasdaq: AWH) announced that its OVA1® ovarian cancer risk assessment test is now recognized as medically necessary by AIM Specialty Health. This new guideline facilitates the preoperative evaluation of pelvic masses, enhancing surgical decisions and patient care. With recent endorsements including New York State Medicaid, the accessibility of OVA1® has significantly increased, particularly among Black women. Aspira aims to address ethnic disparities in ovarian cancer risk assessment, highlighting its commitment to improving women's health outcomes.
Aspira Women’s Health Inc. (Nasdaq: AWH) announced that its OVA1® ovarian cancer risk assessment test is now deemed medically necessary per AIM Specialty Health's guidelines.
This move enhances access for women with pelvic masses and aligns with AIM's efforts to improve healthcare quality. Positive coverage expansions, such as New York State Medicaid, have increased access to OVA1® technology. CEO Valerie Palmieri emphasized the commitment to improving care standards for women.
Aspira Women’s Health Inc. (NASDAQ: AWH) announced promising initial clinical data for its blood-based test OVASight, aimed at assessing the risk of ovarian cancer in women with suspected benign pelvic masses. In a low prevalence population (3.8%), OVASight achieved 89% specificity, 91% sensitivity, and a negative predictive value of 99.6%. These results outperform traditional CA-125 testing in early-stage disease. The data was released during the American Society of Clinical Oncology (ASCO) 2021 virtual meeting, emphasizing the company's commitment to improving women's health.
Aspira Women’s Health, Inc. (Nasdaq: AWH) announced its participation in the William Blair Growth Stock Conference from June 1-3, 2021. The company will present on June 3 at 9:00 am ET. Aspira focuses on innovative testing solutions for women's health, particularly in ovarian cancer risk assessment and pelvic diseases. Their product portfolio includes OVA1® plus and ASPIRA GenetiX™ testing, aimed at improving gynecologic health outcomes. For more details, visit their website.
Aspira Women’s Health Inc. (Nasdaq: AWH) reported Q1 2021 financial results, highlighting a 23% increase in total product and genetics revenue to $1.496 million. OVA1plus tests performed rose by 3% to 3,775. The company initiated a large prospective clinical study with Northwell Health and established a significant commercial agreement with a major women's health network. However, R&D expenses surged by 121% compared to Q1 2020, indicating increased investment in product development. The firm ended the quarter with approximately $59.4 million in cash.
Aspira Women’s Health (Nasdaq: AWH) announced the analytical and initial clinical validation of its OVASight™ blood-based biomarker test for assessing ovarian malignancy risk in women with adnexal masses. The abstract detailing this test will be presented at the ASCO 2021 meeting from June 4-8. The OVASight™ test showcases a high negative predictive value, enhancing clinician confidence in monitoring suspected benign masses. The product is expected to be available in Q4 2021, aiming to replace the CA-125 test.